OBJECTIVES: Combined chemoradiotherapy with or without surgery is frequently performed as a curative treatment in patients with T3-4 locally advanced oesophageal squamous cell carcinoma. Computed tomography (CT) is frequently performed before and after chemoradiotherapy. The aim of this study is to evaluate the utility of the oesophageal wall thickness on CT scans to predict the response to chemoradiotherapy and the treatment outcome in patients with T3-4 locally advanced oesophageal squamous cell carcinoma.
INTRODUCTION
The prognosis of patients with oesophageal cancer is poor, especially for patients with T3-4 oesophageal squamous cell carcinoma [1] . The outcome of patients with locally advanced oesophageal cancer treated with surgery alone is unsatisfactory. The 5-year survival rate is <20% [2] . In an attempt to improve survival, a multimodality approach using combined chemoradiotherapy with and without surgery has been advocated [3, 4] . However, the value of the surgery after chemoradiotherapy remains unclear. Recently, important phase III studies [3, 4] in France and Germany have compared definitive chemoradiotherapy and neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal cancer. The results showed that surgery may not be necessary in patients who respond to chemoradiotherapy, but some patients in the surgery group experienced long-term survival because the tumours could be resected completely when they did not response well to chemoradiotherapy. After neoadjuvant chemoradiotherapy, a pathologically complete response ( pCR) was found in 20-40% of the patients [3] [4] [5] , and it is associated with improved survival [5, 6] . With the development of chemoradiotherapy, a surrogate marker of treatment efficacy becomes important. If tumours are sterilized after chemoradiotherapy, surgery may not be necessary as it can lead to additional postoperative mortality and morbidity [7] [8] [9] . Otherwise, surgery is strongly suggested to eradicate local-regionally residual disease. Therefore, if we can find factors that predict the effect of chemoradiotherapy, a more effective therapeutic strategy can be expected.
The use of computed tomography (CT) to evaluate oesophageal cancer is available in most hospitals. The majority of patients with oesophageal cancer have CT scans of the chest and abdomen as their initial staging investigation. After chemoradiotherapy, CT imaging is frequently repeated to evaluate treatment response and exclude metastatic disease before oesophagectomy. Thus far, few studies have evaluated the utility of oesophageal wall thickness on CT scans to predict the response after neoadjuvant chemoradiotherapy. Swisher et al. [10] showed that post-chemoradiotherapy maximal oesophageal wall thickness is associated with the response to chemoradiotherapy, but the majority of oesophageal cancers in this study are adenocarcinoma, not squamous cell carcinoma. Patients with oesophageal squamous cell carcinoma and adenocarcinoma show a different prognosis after neoadjuvant chemoradiotherapy, and thus should be analysed separately. Unlike adenocarcinoma, in which the achievement of node negative disease after neoadjuvant chemoradiotherapy is the best predictor of clinical outcome, in squamous cell carcinoma of the oesophagus, a pCR in the primary tumour is the best predictor of survival [11, 12] . To the best of our knowledge, a large series study evaluating the role of maximal oesophageal wall thickness on CT scans in patients with T3-4 locally advanced oesophageal squamous cell carcinoma receiving chemoradiotherapy is lacking. In the present study, we evaluated the utility of the oesophageal wall thickness on CT scans to predict the response to chemoradiotherapy in patients with T3-4 locally advanced oesophageal squamous cell carcinoma.
MATERIALS AND METHODS

Patient population
Patients with T3-4 locally advanced oesophageal squamous cell carcinoma who were treated with combined chemoradiotherapy at Kaohsiung Chang Gung Memorial Hospital between January 1998 and December 2008 were retrospectively reviewed. The prerequisite for patients selected for this study was to have had an oesophagectomy after chemoradiotherapy to allow pathologic correlation with CT scans. CT scans performed outside of our hospital were not included because of differences in equipment. During this period, combined chemoradiotherapy was performed in 268 patients with T3-4 locally advanced oesophageal squamous cell carcinoma after oesophageal cancer was diagnosed. Of these 268 patients, 96 patients underwent an oesophagectomy after neoadjuvant chemoradiotherapy, and CT scans before and after chemoradiotherapy were available for 93 patients. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital. Patients were evaluated by a multidisciplinary team including a thoracic surgeon, a medical oncologist, a radiation oncologist, a radiologist and a gastroenterologist. Patients were staged based on the CT scans of the chest and abdomen or endoscopic ultrasound (EUS). EUS is necessary to further confirm T3 oesophageal squamous cell carcinoma if CT scans showed T3 disease. EUS is unnecessary if T4 disease was confirmed by CT scans. The clinical tumor node metastasis stage (TNM) was determined according to the 7th American Joint Committee on Cancer (AJCC) staging system.
Treatment plan
Patients were treated with two cycles of cisplatin and 5-fluorouracil-based chemotherapy and radiotherapy (36 Gy in 20 fractions), concurrently. Each cycle lasted between 3 and 4 weeks. Radiotherapy was delivered in five daily fractions per week of 1.8 Gy during the 4 weeks. Three-dimensional conformal radiotherapy (CRT) via a four-field technique was used for most of the patients. The gross tumour volume (GTV) was defined as the gross tumour and lymph nodes on the simulation CT scan. The clinical target volume (CTV) covered the GTV with a 3-cm craniocaudal and 1-cm radial margin and also the entire mediastinal lymph nodes. For upper or lower third primaries, bilateral supraclavicular lymph nodes or coeliac lymph nodes were also included for prophylactic irradiation. The planning target volume was generated from the CTV with a 1-cm expansion in all directions. The radiotherapy was delivered by LINAC using 6-or 15-MV photons with 1.8 Gy per daily fraction, five fractions per week to a total dose of 36 Gy/20 fractions. Within 3-4 weeks following the end of irradiation, CT scans were performed to assess the treatment response. The multidisciplinary team reviewed the clinical information to determine if the lesions were resectable. If lesions were classified as resectable, surgery was advised 4-6 weeks after the end of preoperative chemoradiotherapy. Patients undergoing surgery had a radical oesophagectomy with cervical oesophagogastrostomy or an Ivor Lewis oesophagectomy with intrathoracic anastomosis, two-field lymphadenectomy and reconstruction of the digestive tract with gastric tube and pylorus drainage procedures. pCR was defined as the complete disappearance of all viable cancer cells in all surgical specimens including the primary oesophageal tumour and lymph nodes.
Multidetector CT
All the patients underwent multidetector CT (MDCT) using the Light Speed 4-MDCT scanner (GE Healthcare, Taipei, Taiwan). Patients were scanned in a supine position in a craniocaudal direction with the arm above the head; the entire thorax from the thoracic inlet to the level of the adrenal glands was studied. The scanning protocol was set to a slice collimation of 2.5-7.5 mm, 0.5-s gantry rotation, 130 kV, 160 mAs, a pitch ratio of 1.5:1 and a field of view of 35 cm. The technician instructed each patient to take three deep breaths before the examination started and to hold their breaths during scanning. In all patients, venous access was achieved through an 18-or 20-gauge IV catheter placed in an antecubital vein. The contrast agent [Omnipaque (iohexol), 350 mg I/ml, Amersham Health] was given via a mechanical power injector at a rate of 2 ml/s with a scanning delay of 25-30 s. After the examination, axial images were reconstructed in 5-mm thick slices for analysis at a setting appropriate for tumour visualization (window level, 40-50 H; window width, 350-400 H).
Image evaluation
A radiologist (W.-C.L.) experienced in the interpretation of CT reviewed all CT scans before and after chemoradiotherapy. Measurements of maximal dimension of the primary tumour/ oesophageal wall thickness were performed retrospectively. The cross-sectional diameter of the thickest part of the lesion was identified. All of these measurements were performed using the PACS imaging display software (Centricity RA1000, GE Healthcare). Maps of the region of interest used for measurement were stored and then confirmed by another radiologist ( J.-L.L.). Observers were blinded to the patients, clinical data and the findings were recorded by consensus. The percentage decrease of maximal oesophageal wall thickness after chemoradiotherapy was determined by the formula: [(pre -post)/pre] × 100 [10] .
Patient follow-up
After the operation, patients were followed at 3-month intervals for the first 2 years, 6-month intervals in the years 3-5 and annually thereafter. Locoregional recurrence is defined as that occurring in the mediastinum or upper abdomen at the site of the previous oesophageal resection and nodal clearance and that occurring in the cervical area where no lymphadenectomy had been performed [13] . Distant recurrence is defined as haematogenous if it developed within a solid organ, or as transcoelomic if it is within the peritoneal cavity [13] . If recurrence was found at more than one site on initial evaluation or was subsequently detected at another site within 30 days, it was defined as occurring synchronously in both areas. Overall survival was calculated from the date of diagnosis until death or last follow-up. Disease-specific survival was measured from the date of diagnosis to the date of death due to cancer. To calculate disease-specific survival, deaths attributed to causes other than oesophageal cancer were censored at the date of death. We used diseasespecific survival for the analyses because it partially controls for competing risks. Disease-free survival was computed from the time of surgery to the diagnosis of recurrent disease or death without evidence of disease recurrence, censoring at the date of death.
Statistical analysis
Statistical analysis was performed using the SPSS 17 software package. The χ 2 test, Fisher's exact test and t-test were used to compare data between the two groups. Multivariate analysis of pCR was performed by stepwise logistic regression, with variables with P < 0.1 being entered into the model. For survival analysis, the Kaplan-Meier method was used for univariate analysis, and the difference between survival curves was tested by a log-rank test. In a stepwise forward fashion, parameters with P < 0.1 at the univariate level were in principle entered into a Cox regression model to analyse their relative prognostic importance. However, as component factors of the 7th AJCC staging system, the 7th T stage and 7th N stage were not introduced in multivariate analyses simultaneously. pCR was also not introduced in multivariate analyses. For all analyses, two-sided tests of significance were used with P < 0.05 considered significant.
RESULTS
Patient characteristics
The clinicopathologic parameters of the 93 patients with CT scans before and after neoadjuvant chemoradiotherapy are described in Table 1 . Fifty (54%) patients had T3 disease, and 43 (46%) patients had T4 disease. After neoadjuvant chemoradiotherapy, 22 (24%) patients achieved a pCR. The median value of maximal oesophageal wall thickness on CT scans was 18.9 mm (range 10.9-36.0 mm) before chemoradiotherapy and 15.5 mm (range 10.1-23.7 mm) after chemoradiotherapy. The median value of percent decrease of maximal oesophageal wall thickness after chemoradiotherapy was 13% (range -17 to 58%). There were no significant associations between pre-chemoradiotherapy maximal oesophageal wall thickness with T stage (T3 or T4), aorta invasion and tracheobronchial invasion before neoadjuvant chemoradiotherapy. There were also no significant associations between post-chemoradiotherapy maximal oesophageal wall thickness with aorta invasion and tracheobronchial invasion pathologically (data not shown). The 3-year overall and diseasespecific survival rates were 37 and 49%. Of these 93 patients, R0, R1 and R2 resections were performed in 80 (86%), 4 (4%) and 9 (10%) patients, respectively. There were no significant associations between R0 resections with pre-chemoradiotherapy maximal oesophageal wall thickness, post-chemoradiotherapy maximal oesophageal wall thickness, and the percent decrease of oesophageal wall thickness after chemoradiothrapy (Table 2) .
Correlation between pCR and clinical parameters
Pre-and post-chemoradiotherapy maximal oesophageal wall thicknesses were significantly correlated with pCR. Patients who achieved pCR after chemoradiotherapy had a significantly thinner oesophageal wall thickness than those who did not (Table 3) . But, the percentage decrease of oesophageal wall thickness after chemoradiothrapy was not significantly different. From the CT evaluation, we tried to develop thresholds for each parameter to predict residual disease after chemoradiotherapy ( patients who did not achieve pCR). Then, we used these thresholds to assess their correlation with pCR. Pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm (P = 0.019) and post-chemoradiotherapy maximal oesophageal wall thickness ≥15 mm (P = 0.032) were significantly associated with residual disease after chemoradiotherapy. T stage, N stage, percentage decrease of oesophageal wall thickness <10%, primary tumour location and tumour grade were not significantly associated with pCR (Table 4 ). The logistic model showed that pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm was independently correlated with residual disease after chemoradiotherapy (P = 0.027, odds ratio: 4.373, 95% confidence interval: 1.184-16.148). For patients with pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm, 29 (91%) of the 32 patients did not achieve pCR after chemoradiotherapy. For patients with post-chemoradiotherapy maximal oesophageal wall thickness ≥15 mm, 50 (83%) of the 60 patients did not achieve pCR after chemoradiotherapy.
Survival analysis
Correlations of patient survivals with parameters on CT scans and various clinicopathological factors at the univariate level are shown in Table 5 . Pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm (P = 0.026, Fig. 1) , and the absence of pCR (P = 0.0005) were significantly related to worse diseasespecific survival. Pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm (P = 0.012), T4 disease (P = 0.014), positive N stage (P = 0.04) and the absence of pCR (P = 0.0002) were significantly related to worse disease-free survival. Prechemoradiotherapy maximal oesophageal wall thickness ≥20 mm (P = 0.0062), T4 disease (P = 0.052) and the absence of pCR (P = 0.0011) were significantly related to worse locoregional recurrence-free survival. Positive N stage (P = 0.051), and the absence of pCR (P = 0.015) were significantly related to worse distance recurrence-free survival.
In multivariate analysis, pre-chemoradiotherapy maximal oesophageal wall thickness ≥20 mm was an independent adverse prognosticator for disease-specific survival (P = 0.029, odds ratio: 2.002, 95% confidence interval: 1.075-3.728), disease-free survival (P = 0.014, odds ratio: 2.068, 95% confidence interval: 1.162-3.681) and locoregional recurrence-free survival (P = 0.009, odds ratio: 2.841, 95% confidence interval: 1.299-6.214). The 3-year disease-specific survival rate was 57 and 35% in patients with pre-chemoradiotherapy maximal oesophageal wall thickness <20 and ≥20 mm, respectively.
DISCUSSION
Oesophageal squamous cell carcinoma is usually diagnosed at an advanced stage [14] . The use of neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy has been increasing in recent years for patients with locally advanced oesophageal squamous cell carcinoma. After chemoradiotherapy, no viable tumours are observed in 20-40% of resected oesophageal tumour specimens. The therapeutic longterm benefit to achieving a pCR is suggested with multiple retrospective series reporting 5-year survivals of 40-60% in those groups of patients when compared with those with specimens containing residual disease [15] . On the other hand, perioperative morbidity and mortality may be increased by neoadjuvant chemoradiotherapy [7, 8] . This phenomenon has caused clinicians to suggest that surgery may be necessary only if the oesophageal tumour is not eradicated completely by chemoradiotherapy. In the study by Swisher et al. [10] , postchemoradiotherapy maximal oesophageal wall thickness is also associated with the response to chemoradiotherapy, but 87% of the oesophageal cancers in this study are adenocarcinoma, not squamous cell carcinoma. Previous studies [16] have reported that these two histological tumour types in oesophageal cancer exhibit different behaviour, and should be analysed separately.
To the best of our knowledge, the role of maximal oesophageal wall thickness on CT scan in patients with T3-4 locally advanced oesophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy has not been well elucidated. In the present study, 91% of patients with pre-treatment maximal oesophageal wall thickness ≥20 mm did not achieve pCR after chemoradiotherapy, and thus oesophgectomy may be planned in advance in this group of patients. The ability to identify this group of patients could allow more appropriate selection of multimodality treatment options. In our study, we did not find the correlation between the percentage decrease of oesophageal wall thickness and pCR. Some patients achieved pCR despite their CT scans not showing significant a decrease of oesophageal wall thickness. The report by Swisher et al. [10] also showed a similar finding. Radiationrelated fibrosis and inflammation may contribute to the inaccuracy of the percentage decrease of oesophageal wall thickness.
In the present study, the response of chemoradiotherapy and treatment outcome in patients with locally advanced oesophageal squamous cell carcinoma was significantly correlated with pre-treatment maximal oesophageal wall thickness. The association between the tumour size and treatment outcome of radiotherapy or chemoradiotherapy has also been reported in head and neck cancer [17, 18] , non-small cell lung cancer [19] and cervical cancer [20] . Before the era of chemoradiotherapy, surgery was the main treatment modality for oesophageal cancer, and the AJCC staging was one of the most widely used staging systems for clinicians to predict the prognosis after oesophagectomy. The AJCC staging system for oesophageal cancer is based on pathologic data treated by primary surgical resection alone [21] . However, Barbour et al. [22] reported that the AJCC staging system for oesophageal cancer is inadequate for patients who receive neoadjuvant chemoradiotherapy. Therefore, our results may provide some useful clinical prognosticators in patients with locally advanced oesophageal squamous cell carcinoma who receive neoadjuvant chemoradiotherapy. It is well known that lymph node metastasis is the important prognostic factor in patients with oesophageal squamous cell carcinoma [23, 24] . A complete response to neoadjuvant chemoradiotherapy also requires regression of any pre-existing lymph node involvement. However, we did not evaluate the correlation between the response to chemoradiotherapy and lymph node involvement on CT scan in the present study because CT scanning alone is unable to predict lymph node involvement clearly [25] .
On the other hand, 42 of 61 patients with prechemoradiotherapy maximal oesophageal wall thickness <20 mm and 21 of 33 patients with post-chemoradiotherapy maximal oesophageal wall thickness <15 mm in the present study did not achieve pCR after neoadjuvant chemoradiotherapy. CT scanning alone is not enough to identify patients who achieve a complete response. Besides, 10 (17%) of 60 patients with post-chemoradiotherapy maximal oesophageal wall thickness ≥15 mm achieved the pCR after chemoradiotherapy. It suggested that a remaining maximal oesophageal wall thickness ≥15 mm did not imply no response to chemoradiotherapy. Therapeutic decisions in patients with T3-4 locally advanced oesophageal squamous cell carcinomas cannot be based on tumour thickness on a CT scan alone. Such therapeutic decisions should also include the findings of EUS, bronchoscope, and fluorine 18-fluorodeoxyglucose positron emission tomography (FDG-PET) whenever possible. Our observations have important limitations. First, the retrospective design of this analysis further justifies the conclusion that a prospective study in the future is needed to define our findings. Second, most of the patients in this study did not have FDG-PET as comparison because it is not routinely supported by Taiwan health insurance.
In conclusion, the majority of the T3-4 locally advanced oesophageal squamous cell carcinoma patients with pre-treatment maximal oesophageal wall thickness ≥20 mm did not achieve pCR after chemoradiotherapy, and thus oesophgectomy may be considered in advance in this group of patients. Besides, pre-treatment maximal oesophageal wall thickness is of independent prognostic value in patients with T3-4 locally advanced oesophageal squamous cell carcinoma who receive neoadjuvant chemoradiotherapy.
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